UroGen Pharma (NASDAQ:URGN) Given New $15.00 Price Target at Guggenheim
UroGen Pharma (NASDAQ:URGN – Get Free Report) had its target price dropped by equities researchers at Guggenheim from $40.00 to $15.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 258.00% from the company’s previous close. Other […]
UroGen Pharma (NASDAQ:URGN – Get Free Report) had its target price dropped by equities researchers at Guggenheim from $40.00 to $15.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 258.00% from the company’s previous close. Other […]
